The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer.
David E. Gerber
No relevant relationships to disclose
Suresh S. Ramalingam
No relevant relationships to disclose
Daniel Morgensztern
No relevant relationships to disclose
Ronan Joseph Kelly
No relevant relationships to disclose
Timothy Francis Burns
No relevant relationships to disclose
Ariel Lopez-Chavez
No relevant relationships to disclose
David R. Spigel
No relevant relationships to disclose
Ahmad Mouhamad Wehbe
No relevant relationships to disclose
Rachel Sorensen
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
David T. Weaver
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
Joanna Horobin
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
Mitchell Keegan
Employment or Leadership Position - Verastem
Stock Ownership - Verastem
Pier P. Scaglioni
No relevant relationships to disclose
D. Ross Camidge
No relevant relationships to disclose